Pond Technologies appoints John M. Farah to board
Dr. Farah has greater than 30 years of experience in health care and the biopharmaceutical industry.
Dr. Farah is currently a senior clinical consultant at Veradigm, an Allscripts business.
He is also a member of the industry advisory board for the Coulter-Drexel Translational Research Partnership Program (Drexel University).
He has advised clients in drug and biologic development and corporate partnering as Managing Director of his own consultancy and in market access and market research with agencies like rjSynergy.
Dr. Farah began advising small to mid-sized firms after 19 years at Cephalon (now Teva) where he became Vice President of international pharmaceutical operations. John has broad expertise in R&D, business development, and ex-U.S. commercialization with specialization in Asia Pacific and Latin American markets.
He had focused on products for neurosciences and pain, hematology and oncology, and infectious and inflammatory disorders for Cephalon.
In addition, Dr. Farah co-led successful intellectual property litigation efforts in Europe and Latin America and was Treasurer and director of Cephalon's political action committee.
Dr. Farah has over 10 years of experience as an independent director on the boards of public U.S. companies including service on audit, compensation, and governance committees.
He is author and inventor on over 40 publications, whitepapers, and patents.
Dr. Farah started his industry career as a research investigator in neurosciences and immune-inflammatory programs at G.D. Searle & Co. (now Pfizer).
Dr. Farah earned his doctorate in physiology from the Uniformed Services University and conducting post-doctoral studies in the Neurological Disorders and Stroke division of the National Institutes of Health. ■